Introduction
Toll-like receptors (TLRs) acting as an initiator of the innate immune response in antigen-presenting cells (APCs) is well known [3] . TLRs are one of the first sensors to recognize pathogen-associated molecular patterns and trigger signal transduction to induce effector molecules, including inflammatory cytokines and chemokines [1] .
Lipopolysaccharide (LPS), a representative virulence factor of gram-negative bacteria, activates both MyD88-dependent and -independent pathways upon recognition by TLR4 [1] . Lipoteichoic acid (LTA), a cell wall component of gram-positive bacteria, is sensed by TLR2 [10] , initiating only the MyD88-dependent signaling pathway mainly via mitogen-associated protein kinase and nuclear factor kappa-B (NF-κB) [2] to produce proinflammatory cytokines such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) [25] .
Numerous studies have examined TLR-mediated immune responses in APCs, including dendritic cells [18, 23, 29] , yet only recently a few reports suggested that T lymphocytes also express TLR2 and TLR4 [9, 19] . Very low levels of TLRs are expressed on naïve T cells, whereas their expression increases in response to T-cell receptor (TCR) stimulation [19] . Effector CD4 + T cells triggered with Pam3CSK4, a TLR2 ligand, induced increases in the cell expansion and production of cytokines, including IL-2, IFN-γ, and TNF-α [19] . In addition, the bacterial lipoprotein, another TLR2 ligand, attenuates the suppressive function of regulatory T cells (Tregs) by downregulating forkhead box P3 (Foxp3) expression [22] . However, other studies have reported conflicting results that the TLR2 ligand increases the suppressive activity through the Tregs [6, 32] . Therefore, these studies clearly left a margin for further study to define the role of TLR2 on T cells. Tregs suppress CD4 and CD8 T cells via a membranebound form of TGF-β in a cell-to-cell contact-dependent manner [34] . TGF-β1 latency-associated peptide (LAP) forms complexes with membrane-bound TGF-β, which can be released as an active form after cleavage by serum proteinases such as plasmin, which increases during the inflammatory response [26, 35] and is used as a marker for the detection of membrane-bound TGF-β [35] .
In this study, we generated effector CD4 + T cells after co-culture with S. aureus-pulsed DCs to examine the impact of LTA treatment on (i) TLR2 expression, and (ii) proliferation and activation, and (iii) the effect of LTAinduced LAP expression in the effector CD4 + T cells.
Materials and Methods

Reagents
Staphylococcus aureus was obtained from the American Type Culture Collection (Manassas, VA, USA), highly purified, and its LTA was produced as previously described [13] . LPS was purchased from Sigma-Aldrich (USA) and SB239063 (p38 inhibitor chemical reagent) from Calbiochem (USA). Recombinant human granulocyte-macrophage stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4) were purchased from R&D Systems (USA). Anti-human CD3, CD4, CD25, CD69, TLR2, TLR4, IFN-γ, IL-13, TGF-β1 LAP, and Foxp3 antibodies were from BD Biosciences (USA). Complete medium containing RPMI-1640 Glutamax medium, fetal bovine serum, and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) was purchased from Invitrogen (USA). A Tcell activation/expansion kit was purchased from Miltenyi Biotec (USA), and anti-human CD2/CD3/CD28 antibody-complex beads (Miltenyi Biotec) were formulated according to the manufacturer's instructions.
Preparation of Human Monocyte-Derived DCs
All experiments involving human blood were approved by the Institutional Review Board of Seoul National University (IRB No. 1107/001-006). Normal adult blood samples were anonymously provided by the Blood Center of the Korean Red Cross. Peripheral blood mononuclear cells (PBMCs) were isolated from human adult blood by density gradient centrifugation (410 ×g for 25 min) using Ficoll-Paque Plus (Amersham Bioscience, UK). CD14 + monocytes (purity >95%) were isolated from PBMCs using a magnetic bead-based positive selection kit (BD Biosciences). The isolated CD14
+ monocytes were cultured in complete medium containing rhIL-4 (500 U/ml) and rhGM-CSF (800 U/ml) for 6 days to generate immature DCs; the medium was changed every 3 days. Immature DCs stimulated with LPS (0.1 µg/ml), LTA (2 µg/ml), or ethanol-killed S. aureus (10 7 CFU/ml) for 2 days became mature [31] .
Characterization of CD4
+ T Cells Co-Cultured with AntigenPulsed DCs CD4 + T cells, isolated from PBMCs using a human CD4 T cell (negative) isolation kit (Miltenyi Biotec), were co-cultured with 1 × 10 5 antigen-pulsed (with LPS, LTA, or S. aureus) DCs for 3 days.
The cells were stained with anti-human CD4 together with either anti-human CD25 and CD69 antibodies as early activation markers or with anti-human TLR2, TLR4, or IFN-γ antibodies. For intracellular staining of IFN-γ, the co-cultured cells were incubated with GolgiStop reagent (BD Biosciences) for the last 10 h of culture. After washing with PBS, the cells were stained with anti-human CD4 antibody, permeabilized with Cytofix/Cytoperm solution (BD Biosciences), stained with anti-human IFN-γ antibody, and then analyzed using flow cytometry (FACSCalibur, BD Biosciences).
To examine the proliferation of CD4 + T cells, the cells were labeled with CFSE and cultured with LPS-, LTA-or S. aureuspulsed DCs for 3 days. Then, the cells were stained with antihuman CD4 antibody and examined for their expansion using flow cytometry.
Isolation of Effector CD4
+ T Cells After Co-Cultured with
Mature DCs
Effector CD4 + T cells were isolated after co-culture with CD4 + T cells with S. aureus-pulsed DCs for 3 days, using anti-human CD4 antibody-conjugated magnetic beads (BD Biosciences). Isolated cells were stained with anti-human CD3 and CD4 antibodies for 15 min and their purity was determined (above 97%, data not shown) by flow cytometry.
Characterization of Effector CD4
+ 
Proliferation of Effector CD4 + T Cells
To measure the proliferation, effector CD4 + T cells were stimulated with LTA with/without a TGF-β R1 kinase inhibitor (Calbiochem). Briefly, the cells (1 × 10 5 /well) were cultured on 96-well plates and stimulated with anti-human CD2/CD3/CD28 antibody-complex beads (1:20 bead to cell ratio) together with 2 µg/ml LTA for 3 days. In some inhibitor tests, the cells were pretreated with a TGF-β R1 kinase inhibitor for 1 h before the LTA treatment. After the culture, 20 µl of MTT (Sigma-Aldrich) solution (5 mg/ml in PBS) was added to each well and the plates were incubated for an additional 4 h at 37 o C in a humidified incubator with 5% CO 2 . After removing the supernatant, the blue formazan product was dissolved in 200 µl of dimethyl sulfoxide per well for 5 min. Changes in color were measured using a microplate reader (Molecular Device, USA).
p38 Signaling for TGF-β1 LAP Induced by LTA Treatment
To identify the role of p38 signaling in effector CD4 + T cells treated with LTA to induce TGF-β1 LAP, effector CD4 + T cells were pretreated with SB239063 (p38 inhibitor) for 1 h, followed by
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addition of LTA (2 µg/ml) and incubation for a further 2 days. Then, the cells were stained with anti-human CD25 and TGF-β1 LAP antibodies for 15 min. The CD25 + cells were gated and the proportion of TGF-β1 LAP + cells analyzed using flow cytometry.
Statistical Analysis
All data are presented as means ± standard deviations for each treatment group. Statistical significance was evaluated using a 2-tailed paired t-test. A value of p < 0.05 was considered to indicate statistical significance.
Results
Induction of Effector CD4
+ T Cells After Co-Culture with S. aureus-Pulsed DCs DCs have the best ability for presenting antigenic molecules to T lymphocytes. In the previous study, we observed that LTA, LPS, or ethanol-killed S. aureus induced maturation of DCs, which can activate CD4 + T cells though presenting antigenic molecules [31] . After recognizing antigenic molecules loaded on the major histocompatibility complex (MHC) of mature DCs, CD4 + T cells are activated,
producing some cytokines such as IFN-γ, IL-2, and IL-4. In addition, the surface expression of activation markers, such as CD25 and CD69, increased [14] . To generate effector T cells in vitro, human CD4 + T cells were co-cultured with LTA-, LPS-, or S. aureus-pulsed DCs. As shown in Fig. 1A , CD4 + T cells co-cultured with LTA-or LPS-pulsed DCs produced slightly higher IFN-γ levels compared with that of control CD4 + T cells co-cultured with immature DCs, whereas CD4 + T cells co-cultured with S. aureus-pulsed
DCs produced about 8-fold higher IFN-γ than that in the immature DC control. A high percentage of CD4 + T cells with CD25 + and/or CD69 + were also detected when cocultured with S. aureus-pulsed DCs, compared with that of other groups (Fig. 1B) . Next, we measured the proliferation of CFSE-labeled CD4 + T cells co-cultured with LTA-, LPS-, or S. aureus-pulsed DCs. Similar to Fig. 1A , greater proliferation was detected in CD4 + T cells co-cultured with S. aureus-pulsed DCs than those of the other CD4 + T-cell groups (Fig. 1C) . These results show that although LTA and LPS can induce the maturation of DCs, LTA-or LPSpulsed DCs could not activate CD4 + T cells as compared with S. aureus-pulsed DCs. A recent study suggested that effector CD4 + T cells stimulated by TCR ligation express more TLRs compared with naïve CD4 + T cells [19] .
In contrast to LPS or LTA stimulation, inactivated S. aureus and its antigenic molecules, including enterotoxin B and peptidoglycan, increased the induction and proliferation of antigen-specific CD4 + T cells [20, 24, 33] , suggesting that S. aureus could not only activate DCs but also directly stimulate TCR signaling in T cells. Therefore, we examined whether the expression of TLRs are changed on CD4 + T cells when co-cultured with S. aureus-pulsed DCs, since LTA-or LPS-pulsed DCs had no effect to activate CD4 + T cells. The results showed that the expressions of TLR2 and TLR4 were higher (Fig. 1D ), coincident with an increased level of CD25 (Fig. 1E) , on CD4 + T cells co-cultured with S. + T cells using magnetic beads after coculturing T cells with S. aureus-pulsed DCs. Since the dose of LTA or LPS used to pulse DCs in the present study had a minimal activating effect on T cells ( [31] and Fig. 1 ), effector CD4 + T cells co-cultured with S. aureus-pulsed DCs were used for further study. No apparent apoptosis was detected in isolated CD4 + T cells after the stimulation (data not shown). The cells were then gated on CD25, the early activation marker, and IFN-γ, IL-13, TGF-β1 LAP, and Foxp3 expressions were analyzed. IFN-γ and IL-13 productions were not changed in LTA-and LPS-treated effector CD4 + T cells compared with control cells, whereas TGF-β1 LAP and Foxp3 expression increased by approximately 2-fold in LTA-treated effector CD4 + T cells but not in LPStreated cells (Fig. 2) . These results indicate that LTA could induce the activation and/or differentiation of Tregs.
Suppression of Effector CD4 + T-Cell Proliferation by
TGF-β1 LAP Induced by LTA Treatment Next, we treated effector CD4 + T cells with various concentrations (0, 1, 2, and 4 µg/ml) of LTA to further validate the TGF-β1 LAP production in effector CD4 + T cells.
TGF-β1 LAP production increased to the greatest extent when 2 µg/ml LTA was added (Fig. 3A) , whereas the soluble TGF-β1 level remained unchanged (data not shown).
We treated the cells with a specific p38 inhibitor prior to the LTA treatment to identify the signaling pathway that underlies TGF-β1 LAP expression in effector CD4 + T cells, because p38 signaling has been implicated in TGF-β1 
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production in effector T cells [21] . As a result, the LTAinduced production of TGF-β1 LAP was decreased in effector CD4 + T cells compared with that in cells that were not treated with the p38 inhibitor (Fig. 3B) . TGF-β1 LAP and soluble TGF-β1 are important sources of the cytokines that suppress T-cell proliferation and differentiation into Tregs [35] . Therefore, we treated effector CD4 + T cells for 3 days with LTA and low-dose anti-CD3/ CD2/CD28 antibody-complexed beads (1:20 bead-to-cell ratio) to examine the ability of TGF-β1 LAP to regulate Tcell expansion. The results showed that the proliferation decreased significantly (p < 0.05) when cells were treated with LTA (Fig. 3C) . Next, the cells were pretreated with a TGF-β R1 kinase inhibitor before LTA treatment, and the proliferation of effector CD4 + T cells was examined.
Interestingly, blocking the TGF-β receptor did not inhibit the proliferation of cells treated with LTA (p < 0.05), compared with that of untreated cells (Fig. 3D) . These results indicate that p38 signaling is responsible for LTAinduced TGF-β LAP, which inhibits the expansion of effector CD4 + T cells. LTA (0 or 2 µg/ml) or anti-human CD2/CD3/CD28 antibody-complex beads was measured using the MTT assay. Proliferation levels are expressed as a percentage of the color intensity that resulted from LTA (2 µg/ml) treatment relative to that of untreated controls. *Indicates statistically significant at p < 0.05 compared with the control.
Discussion
The major findings of our study were (i) S. aureuspulsed DCs caused increased expressions of TLR2 and TLR4 on activated CD4
+ T cells, (ii) LTA, but not LPS, induced an increase of TGF-β1 LAP and Foxp3 in effector CD4 + T cells, and (iii) LTA-mediated TGF-β1 LAP production through p38 signaling inhibited effector CD4 + T cell proliferation.
LPS is an endotoxin derived from gram-negative bacteria that induces sepsis in infected hosts. In 1998, TLR4 was discovered as an LPS-recognition receptor that induces the expression of proinflammatory cytokines [28] . LTA, on the other hand, is a surface molecule expressed uniquely on gram-positive bacteria [15] . A critical role for TLR2 signaling was demonstrated in TLR2-deficient mice that are highly susceptible to invasion by gram-positive bacteria [36] . The direct effect of TLR signaling in T lymphocytes has been reported, in which treatment with TLR2 ligands induces the activation and survival of T cells [12, 16] . Intriguingly, TLR2 signaling in Tregs is also suggested to induce the proliferation and functional activation of Tregs [27] . Accordingly, these findings led us to hypothesize that LTA might be involved in not only the action of antigenpresenting cells but also in direct regulation of effector T cells through the TLR signaling pathway. To clarify this, we examined the TLR expression, cytokine production, and proliferation in activated CD4
+ T cells after LTA treatment.
We observed that CD4 + T cells activated with S. aureuspulsed DCs increased the production of IFN-γ, the surface expression of CD25 and CD69, and the proliferation, compared with those of CD4 + T cells activated with LTAor LPS-pulsed DCs. Although it has been suggested that TLR1, 2, 3, 4, 5, 7, and 9 mRNA are induced when human T cells are activated [8] , poly I:C (a TLR3 ligand) or CpG (a TLR9 ligand) fail to stimulate activated or memory T cells [19] . When we measured the expression levels of TLR2 and TLR4, they were increased on the effector CD4 + T cells cocultured with S. aureus-pulsed DCs. It is possible that the effector CD4 + T cells could directly interact with TLR2 or TLR4 ligands. Therefore, we examined whether LTA or LPS can influence the production of cytokines and transcript factors. A recent study showed that heat shock protein 60 (HSP60), known as a TLR2 ligand that enhances the suppressive activity of Tregs, inhibits the proliferation of CD4 + CD25 -T cells [37] . To test whether LTA could enhance
Tregs activity, effector T cells were treated with LTA, and then the expression levels of IFN-γ, IL-13, TGF-β1 LAP, and Foxp3 were measured. We observed that LTA increased TGF-β1 LAP and Foxp3 expressions in effector CD4 + T cells, whereas it did not increase IFN-γ and IL-13. Interestingly, LPS did not increase TGF-β1 LAP or Foxp3 in effector CD4 + T cells. LPS has no effect on the function of Tregs [7, 19, 32] , which suggested that the lack of a coreceptor, such as CD14, could interfere with and/or reduce the LPS recognition in CD4 + T cells. It is possible that the balance between Myd 88-dependent (by LPS and LTA) and -independent (by LPS) signaling plays a critical role on this, since LTA acts towards tolerance, whereas LPS acts towards inflammatory responses. Furthermore, it has been shown that negative regulators induced by LPS [4] are different from those by LTA [17] . Foxp3 and TGF-β1 are key molecules in differentiation and proliferation of Tregs [30] . Foxp3 is the transcriptional factor that induces the differentiation of Tregs producing TGF-β [34] and TGF-β1 LAP [26] which cause a suppressive feature. We demonstrated that LTA increased TGF-β1 LAP production in a dose-dependent manner on effector CD4 + T cells through p38 signaling. Furthermore, we showed that the significant suppression of effector CD4 + T cell proliferation after LTA treatment is dependent on TGF-β signaling. Our findings suggest that LTA suppressed effector CD4 + T cell proliferation by enhancing TGF-β1 LAP production. The suppressive effect of LTA on the proliferation of CD4 + T cells could be a type of immune-evading strategy to increase the viability and infectivity of S. aureus. The immune-escaping mechanism by intracellular bacteria has been well defined, including the cytotoxicity of toxin(s) to host cells and protein A-mediated resistance to phagocytic activity [11] . Indeed, it has been demonstrated that TLR ligands downregulate T-cell proliferation by enhancing the suppressive function of Tregs [5, 7, 32] . Furthermore, the p38 signaling pathway is involved in TGF-β1 production and the suppressive functions of Tregs [35] . Therefore, we investigated the relationship between LTA and the p38 signaling pathways for the induction of TGF-β1 LAP in effector CD4
+ T cells. Inhibition of the p38 pathway led to decreased TGF-β1 LAP production, indicating that p38 mediates LTA-induced TGF-β1 LAP production in effector CD4 + T-cells.
In conclusion, effector CD4 + T cells expressed TLR2 and TLR4 after LTA treatment, and LTA, but not LPS, treatment suppressed effector CD4 + T cell proliferation by enhancing TGF-β1 LAP production through the p38 signaling pathway.
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